Indication

Chronic eosinophilic leukemia

Chronic eosinophilic leukemia is a rare myeloproliferative neoplasm characterized by the autonomous, clonal overproduction of eosinophils within the bone marrow, peripheral blood, and tissues. Read more about Chronic eosinophilic leukemia

28 drugs 27 manufacturers

Advertisement

Drugs that treat it

Common Chronic eosinophilic leukemia therapies.

Showing 1–9 of 28 drugs

GLEEVEC (imatinib mesylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Novartis Pharmaceuticals

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
SUN PHARMA GLOB

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
APOTEX CORP

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
TEVA USA

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Mylan Pharmaceuticals

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
MYLAN INSTITUTI

IMATINIB MESYLATE

PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
NORTHSTAR RX LL

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Major Pharamceuticals

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
DR.REDDY'S LAB
Filter & compare in the drug finder →Opens the drug finder with Chronic eosinophilic leukemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Chronic eosinophilic leukemia.

Chronic eosinophilic leukemia is a rare myeloproliferative neoplasm characterized by the autonomous, clonal overproduction of eosinophils within the bone marrow, peripheral blood, and tissues.

Primarily affecting adults, the disease involves persistent hypereosinophilia accompanied by cytogenetic abnormalities, somatic driver mutations, or elevated blast counts, while excluding reactive causes and distinct myeloid neoplasms defined by rearrangements such as *PDGFRA*, *PDGFRB*, *FGFR1*, or *PCM1::JAK2*.

Widespread infiltration of tissues by mature and immature eosinophils releases cytotoxic granules, commonly causing organ dysfunction and damage across the cardiovascular system, central nervous system, lungs, skin, and gastrointestinal tract.

Personalize your experience

Follow Chronic eosinophilic leukemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it